Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00821054 · ClinicalTrials.gov registry record · Phase 1
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00821054 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants.
The verdict
NCT00821054, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will be a randomized 3-treatment, cross-over study to evaluate the bioavailability of lapatinib administered after a high or low-fat meal.
Interventions
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-03-06 |
| Est. Completion | 2011-03-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00821054
The ClinicalTrials.gov registry entry for NCT00821054 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lapatinib is the first listed.
NCT00821054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00821054 about?
NCT00821054 is a clinical study titled "A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients". This study will be a randomized 3-treatment, cross-over study to evaluate the bioavailability of lapatinib administered after a high or low-fat meal.
What is the current status of trial NCT00821054?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-03-06. Estimated completion is 2011-03-22.
What interventions are being tested in trial NCT00821054?
The interventions under investigation include: Lapatinib (DRUG).
Who is sponsoring clinical trial NCT00821054?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.